Mobil medical is administering Monoclonal Antibody Treatments (GSK Sotrovimab) to qualifying residents who have been exposed to or tested positive for COVD-19.
The FDA has issued Emergency Use Authorization (EUA) to permit the emergency use of GSK Sotrovimab for the treatment of mild to moderate coronavirus disease.
- This is NOT a substitute for vaccine against COVID-19
- This is NOT authorized for pre-exposure prophylaxis for prevention of COVID-19.
Monoclonal Antibodies are laboratory-produced molecules that act as substitute antibodies which can restore, enhance or mimic the immune system’s attack on cells. Monoclonal antibodies for COVID-19 may block the virus that causes COVID-19 from attaching to human cells, making it more difficult for the virus to reproduce and cause harm. Monoclonal antibodies may also neutralize a virus.
How Monoclonal Antibodies Work